Anticancer drug resistance: An update and perspective

Adrian, 2006, Allosteric inhibitors of Bcr-abl-dependent cell proliferation, Nat. Chem. Biol., 2, 95, 10.1038/nchembio760

Aissa, 2021, Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer, Nat. Commun., 12, 1628, 10.1038/s41467-021-21884-z

Akdemir, 2020, Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer, Nat. Genet., 52, 294, 10.1038/s41588-019-0564-y

Akdemir, 2020, Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure, Nat. Genet., 52, 1178, 10.1038/s41588-020-0708-0

Alberts, 2002, Cancer as a microevolutionary process

Aleksakhina, 2019, Mechanisms of acquired tumor drug resistance, Biochim. Biophys. Acta Rev. Cancer, 1872, 188310, 10.1016/j.bbcan.2019.188310

Altmuller, 2017, Genotype and phenotype spectrum of NRAS germline variants, Eur. J. Hum. Genet., 25, 823, 10.1038/ejhg.2017.65

Andrei, 2020, Advanced technological tools to study multidrug resistance in cancer, Drug Resist. Updat., 48, 100658, 10.1016/j.drup.2019.100658

Arruabarrena-Aristorena, 2020, FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer, Cancer Cell, 38, 534, 10.1016/j.ccell.2020.08.003

Assaraf, 1989, Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate, J. Biol. Chem., 264, 18326, 10.1016/S0021-9258(18)51467-8

Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat., 46, 100645, 10.1016/j.drup.2019.100645

Awad, 2021, Acquired resistance to KRAS(G12C) inhibition in cancer, N. Engl. J. Med., 384, 2382, 10.1056/NEJMoa2105281

Bailey, 2018, Comprehensive characterization of cancer driver genes and mutations, Cell, 173, e318

Bar-Zeev, 2017, Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance, Drug Resist. Updat., 31, 15, 10.1016/j.drup.2017.05.002

Baylin, 2011, A decade of exploring the cancer epigenome - biological and translational implications, Nat. Rev. Cancer, 11, 726, 10.1038/nrc3130

Beckman, 2020, Rare mutations in cancer drug resistance and implications for therapy, Clin. Pharmacol. Ther., 108, 437, 10.1002/cpt.1938

Bennett, 2018, Targeting epigenetics in cancer, Annu. Rev. Pharmacol. Toxicol., 58, 187, 10.1146/annurev-pharmtox-010716-105106

Bera, 2019, Structural basis of the atypical activation mechanism of KRAS(V14I), J. Biol. Chem., 294, 13964, 10.1074/jbc.RA119.009131

Bhang, 2015, Studying clonal dynamics in response to cancer therapy using high-complexity barcoding, Nat. Med., 21, 440, 10.1038/nm.3841

Bhattacharya, 2021, Group behavior and emergence of cancer drug resistance, Trends Cancer, 7, 323, 10.1016/j.trecan.2021.01.009

Blons, 2014, Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Ann. Oncol., 25, 2378, 10.1093/annonc/mdu464

Bournet, 2016, KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma, Clin. Transl. Gastroenterol., 7, e157, 10.1038/ctg.2016.18

Bousquet, 2013, Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis, Cancer Chemother. Pharmacol., 72, 1183, 10.1007/s00280-013-2300-0

Bram, 2007, C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells, Biochem. Pharmacol., 74, 41, 10.1016/j.bcp.2007.03.028

Brown, 2019, Finding driver mutations in cancer: elucidating the role of background mutational processes, PLoS Comput. Biol., 15, 10.1371/journal.pcbi.1006981

Buck, 2021, Cross-resistance and drug sequence in prostate cancer, Drug Resist. Updat., 56, 100761, 10.1016/j.drup.2021.100761

Burchert, 2007, Roots of imatinib resistance: a question of self-renewal?, Drug Resist. Updat., 10, 152, 10.1016/j.drup.2007.06.001

Burd, 2014, Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma, Cancer Discov., 4, 1418, 10.1158/2159-8290.CD-14-0729

Carrera, 2019, The cell biology behind the oncogenic PIP3 lipids, J. Cell. Sci., 132

Chen, 2004, A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors, Cancer Res., 64, 5913, 10.1158/0008-5472.CAN-04-0085

Chen, 2020, Comprehensive assessment of computational algorithms in predicting cancer driver mutations, Genome Biol., 21, 43, 10.1186/s13059-020-01954-z

Cheng, 2019, Personal mutanomes meet modern oncology drug discovery and precision health, Pharmacol. Rev., 71, 1, 10.1124/pr.118.016253

Cheng, 2021, Comprehensive characterization of protein-protein interactions perturbed by disease mutations, Nat. Genet., 53, 342, 10.1038/s41588-020-00774-y

Chiappa, 2021, Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer, Drug Resist. Updat., 55, 100744, 10.1016/j.drup.2021.100744

Ciardiello, 2008, EGFR antagonists in cancer treatment, N. Engl. J. Med., 358, 1160, 10.1056/NEJMra0707704

Cools, 2003, A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N. Engl. J. Med., 348, 1201, 10.1056/NEJMoa025217

Cree, 2017, Molecular chess? Hallmarks of anti-cancer drug resistance, BMC Cancer, 17, 10, 10.1186/s12885-016-2999-1

Crudden, 2015, The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?, Growth Horm. IGF Res., 25, 2, 10.1016/j.ghir.2014.10.002

Czarnecka, 2019, Metastatic tumor burden and loci as predictors of first line sunitinib treatment efficacy in patients with renal cell carcinoma, Sci. Rep., 9, 7754, 10.1038/s41598-019-44226-y

Dana-Farber Cancer Institute, 2021

Das, 2021, Therapeutic strategies to overcome taxane resistance in cancer, Drug Resist. Updat., 55, 100754, 10.1016/j.drup.2021.100754

Dawson, 2012, Cancer epigenetics: from mechanism to therapy, Cell, 150, 12, 10.1016/j.cell.2012.06.013

Der, 2014

Di Nicolantonio, 2005, Cancer cell adaptation to chemotherapy, BMC Cancer, 5, 78, 10.1186/1471-2407-5-78

Du, 2020, Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels, Biosci. Rep., 40, 10.1042/BSR20200401

Dunnett-Kane, 2021, Mechanisms of resistance to KRAS(G12C) inhibitors, Cancers (Basel), 13, 151, 10.3390/cancers13010151

Easwaran, 2014, Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance, Mol. Cell, 54, 716, 10.1016/j.molcel.2014.05.015

Eberle, 2007, Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches, Drug Resist. Updat., 10, 218, 10.1016/j.drup.2007.09.001

Eide, 2019, Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants, Cancer Cell, 36, e435

Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478

Fardi, 2018, Epigenetic mechanisms as a new approach in cancer treatment: an updated review, Genes Dis., 5, 304, 10.1016/j.gendis.2018.06.003

Feinberg, 2016, Epigenetic modulators, modifiers and mediators in cancer aetiology and progression, Nat. Rev. Genet., 17, 284, 10.1038/nrg.2016.13

Flavahan, 2017, Epigenetic plasticity and the hallmarks of cancer, Science, 357, 10.1126/science.aal2380

Friedman, 2016, Drug resistance in cancer: molecular evolution and compensatory proliferation, Oncotarget, 7, 11746, 10.18632/oncotarget.7459

Gao, 2021, Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function, Drug Resist. Updat., 57, 100770, 10.1016/j.drup.2021.100770

Garraway, 2012, Circumventing cancer drug resistance in the era of personalized medicine, Cancer Discov., 2, 214, 10.1158/2159-8290.CD-12-0012

Gatenby, 2018, The evolution and ecology of resistance in cancer therapy, Cold Spring Harb. Perspect. Med., 8, 10.1101/cshperspect.a033415

Genovese, 2017, Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins, Drug Resist. Updat., 32, 23, 10.1016/j.drup.2017.10.003

Gerstung, 2020, The evolutionary history of 2,658 cancers, Nature, 578, 122, 10.1038/s41586-019-1907-7

Getzenberg, 2011, Changing the energy habitat of the cancer cell in order to impact therapeutic resistance, Mol. Pharm., 8, 2089, 10.1021/mp200310u

Geyer, 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N. Engl. J. Med., 355, 2733, 10.1056/NEJMoa064320

Gibbs, 1984, Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules, Proc. Natl. Acad. Sci. U. S. A., 81, 5704, 10.1073/pnas.81.18.5704

Gillis, 2016, The pharmacogenomics of drug resistance to protein kinase inhibitors, Drug Resist. Updat., 28, 28, 10.1016/j.drup.2016.06.008

Glaysher, 2009, Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC), BMC Cancer, 9, 300, 10.1186/1471-2407-9-300

Glaysher, 2010, Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy (for the NHS Collaborative Research Programme for Predictive Oncology), Br. J. Cancer, 103, 656, 10.1038/sj.bjc.6605817

Goler-Baron, 2012, Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells, Biochem. Pharmacol., 83, 1340, 10.1016/j.bcp.2012.01.033

Gonen, 2012, Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance, Drug Resist. Updat., 15, 183, 10.1016/j.drup.2012.07.002

Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538

Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929

Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706

Gremke, 2020, mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability, Nat. Commun., 11, 4684, 10.1038/s41467-020-18504-7

Haider, 2020, Drug resistance in cancer: mechanisms and tackling strategies, Pharmacol. Rep., 72, 1125, 10.1007/s43440-020-00138-7

Haigis, 2017, KRAS alleles: the devil is in the detail, Trends Cancer, 3, 686, 10.1016/j.trecan.2017.08.006

Harbinski, 2012, Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth, Cancer Discov., 2, 948, 10.1158/2159-8290.CD-12-0237

Hata, 2016, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat. Med., 22, 262, 10.1038/nm.4040

Haupt, 2021, Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure, PLoS Comput. Biol., 17, 10.1371/journal.pcbi.1008970

Hobbs, 2016, RAS isoforms and mutations in cancer at a glance, J. Cell. Sci., 129, 1287, 10.1242/jcs.182873

Housman, 2014, Drug resistance in cancer: an overview, Cancers (Basel), 6, 1769, 10.3390/cancers6031769

Hudis, 2007, Trastuzumab--mechanism of action and use in clinical practice, N. Engl. J. Med., 357, 39, 10.1056/NEJMra043186

Hussein, 2021, The role of endolysosomal trafficking in anticancer drug resistance, Drug Resist. Updat., 57, 100769, 10.1016/j.drup.2021.100769

Ifergan, 2005, Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance, Cancer Res., 65, 10952, 10.1158/0008-5472.CAN-05-2021

Jang, 2021, The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane, iScience, 24, 102438, 10.1016/j.isci.2021.102438

Jiang, 2020, Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs, Drug Resist. Updat., 50, 100683, 10.1016/j.drup.2020.100683

Jiang, 2021, Emerging role of autophagy in anti-tumor immunity: implications for the modulation of immunotherapy resistance, Drug Resist. Updat., 56, 100752, 10.1016/j.drup.2021.100752

Jin, 2020, The updated landscape of tumor microenvironment and drug repurposing, Signal Transduct. Target. Ther., 5, 166, 10.1038/s41392-020-00280-x

Johnson, 2014, Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma, Science, 343, 189, 10.1126/science.1239947

Jonker, 2007, Cetuximab for the treatment of colorectal cancer, N. Engl. J. Med., 357, 2040, 10.1056/NEJMoa071834

Kaemmerer, 2021, Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy, Drug Discov. Today, 26, 663, 10.1016/j.drudis.2020.11.030

Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N. Engl. J. Med., 359, 1757, 10.1056/NEJMoa0804385

Kim, 2021, Chapter five - FPGA based neural network accelerators, Adv. Comp., 122, 135, 10.1016/bs.adcom.2020.11.002

Kim, 2019, AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells, Cell Death Dis., 10, 361, 10.1038/s41419-019-1601-6

Kim, 2021, PubChem in 2021: new data content and improved web interfaces, Nucleic Acids Res., 49, D1388, 10.1093/nar/gkaa971

Knight, 2010, Targeting the cancer kinome through polypharmacology, Nat. Rev. Cancer, 10, 130, 10.1038/nrc2787

Knoechel, 2015, Metabolic mechanisms of drug resistance in leukemia, Cell Metab., 22, 759, 10.1016/j.cmet.2015.10.005

Kohsaka, 2017, A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer, Sci. Transl. Med., 9, 10.1126/scitranslmed.aan6566

Kumar, 2016, Epigenomic regulation of oncogenesis by chromatin remodeling, Oncogene, 35, 4423, 10.1038/onc.2015.513

La Monica, 2019, Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC, J. Exp. Clin. Cancer Res., 38, 222, 10.1186/s13046-019-1240-x

Lampson, 2013, Rare codons regulate KRas oncogenesis, Curr. Biol., 23, 70, 10.1016/j.cub.2012.11.031

Lantermann, 2015, Inhibition of casein kinase 1 alpha prevents acquired drug resistance to erlotinib in EGFR-Mutant non-small cell lung cancer, Cancer Res., 75, 4937, 10.1158/0008-5472.CAN-15-1113

Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213

Le Tourneau, 2012, Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents, Br. J. Cancer, 106, 854, 10.1038/bjc.2012.10

Lee, 2012, Starvation, detoxification, and multidrug resistance in cancer therapy, Drug Resist. Updat., 15, 114, 10.1016/j.drup.2012.01.004

Lee, 2020, Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity, Int. J. Mol. Sci., 21, 1102, 10.3390/ijms21031102

Levin, 2021, Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance, Cancer Cell Int., 21, 53, 10.1186/s12935-021-01746-w

Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, Drug Resist. Updat., 27, 14, 10.1016/j.drup.2016.05.001

Li, 2020, Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification, Drug Resist. Updat., 53, 10.1016/j.drup.2020.100720

Lien, 2017, PI3K signaling in cancer: beyond AKT, Curr. Opin. Cell Biol., 45, 62, 10.1016/j.ceb.2017.02.007

Lim, 2019, Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy, J. Hematol. Oncol., 12, 134, 10.1186/s13045-019-0818-2

Liu, 2020, Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes, PLoS Comput. Biol., 16, 10.1371/journal.pcbi.1007701

Loeb, 2019, Extensive subclonal mutational diversity in human colorectal cancer and its significance, Proc. Natl. Acad. Sci. U. S. A., 116, 26863, 10.1073/pnas.1910301116

Long, 2020, Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia, Drug Resist. Updat., 52, 10.1016/j.drup.2020.100703

Lu, 2016, Ras conformational ensembles, allostery, and signaling, Chem. Rev., 116, 6607, 10.1021/acs.chemrev.5b00542

Madsen, 2019, Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner, Proc. Natl. Acad. Sci. U. S. A., 116, 8380, 10.1073/pnas.1821093116

Makova, 2015, The effects of chromatin organization on variation in mutation rates in the genome, Nat. Rev. Genet., 16, 213, 10.1038/nrg3890

Mansoori, 2017, The different mechanisms of cancer drug resistance: a brief review, Adv. Pharm. Bull., 7, 339, 10.15171/apb.2017.041

Martincorena, 2015, Somatic mutation in cancer and normal cells, Science, 349, 1483, 10.1126/science.aab4082

Mateo, 2020, Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns, Genome Med., 12, 78, 10.1186/s13073-020-00774-x

Mellinghoff, 2005, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors, N. Engl. J. Med., 353, 2012, 10.1056/NEJMoa051918

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med., 357, 2666, 10.1056/NEJMoa072113

Mitchell, 2018, Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal, Cell, 173, e617

Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 25, 1960, 10.1200/JCO.2006.07.9525

Morjaria, 2021, Driver mutations in oncogenesis, Int. J. Mol. Immuno Oncol., 6, 100, 10.25259/IJMIO_26_2020

Munoz-Maldonado, 2019, A comparative analysis of individual RAS mutations in cancer biology, Front. Oncol., 9, 1088, 10.3389/fonc.2019.01088

Narayanan, 2020, Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance, Drug Resist. Updat., 48, 100663, 10.1016/j.drup.2019.100663

National Cancer Institute, 2020

Nebbioso, 2018, Cancer epigenetics: moving forward, PLoS Genet., 14, 10.1371/journal.pgen.1007362

Neel, 2017, Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma, NPJ Precis. Oncol., 1, 3, 10.1038/s41698-017-0007-0

Newlaczyl, 2016

Nguyen, 2021, A comparative study of operational engineering for environmental and compute-intensive applications, Array, 12, 100096, 10.1016/j.array.2021.100096

Nicolini, 2013, The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis, Haematologica, 98, 1510, 10.3324/haematol.2012.080234

Nussinov, 2014, Unraveling structural mechanisms of allosteric drug action, Trends Pharmacol. Sci., 35, 256, 10.1016/j.tips.2014.03.006

Nussinov, 2015, ’Latent drivers’ expand the cancer mutational landscape, Curr. Opin. Struct. Biol., 32, 25, 10.1016/j.sbi.2015.01.004

Nussinov, 2014, The structural basis for cancer treatment decisions, Oncotarget, 5, 7285, 10.18632/oncotarget.2439

Nussinov, 2017, A new view of pathway-driven drug resistance in tumor proliferation, Trends Pharmacol. Sci., 38, 427, 10.1016/j.tips.2017.02.001

Nussinov, 2018, Oncogenic ras isoforms signaling specificity at the membrane, Cancer Res., 78, 593, 10.1158/0008-5472.CAN-17-2727

Nussinov, 2019, Precision medicine review: rare driver mutations and their biophysical classification, Biophys. Rev., 11, 5, 10.1007/s12551-018-0496-2

Nussinov, 2019, Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers, PLoS Comput. Biol., 15

Nussinov, 2019, Why Are Some Driver Mutations Rare?, Trends Pharmacol. Sci., 40, 919, 10.1016/j.tips.2019.10.003

Nussinov, 2020, Are Parallel Proliferation Pathways Redundant?, Trends Biochem. Sci., 45, 554, 10.1016/j.tibs.2020.03.013

Nussinov, 2020, Autoinhibition can identify rare driver mutations and advise pharmacology, FASEB J., 34, 16, 10.1096/fj.201901341R

Nussinov, 2021, A new precision medicine initiative at the dawn of exascale computing, Signal Transduct. Target. Ther., 6, 3, 10.1038/s41392-020-00420-3

Nussinov, 2021, Drugging multiple same-allele driver mutations in cancer, Expert Opin. Drug Discov., 16, 1, 10.1080/17460441.2021.1905628

Nussinov, 2021, Ras isoform-specific expression, chromatin accessibility, and signaling, Biophys. Rev., 13, 489, 10.1007/s12551-021-00817-6

O’Hare, 2005, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res., 65, 4500, 10.1158/0008-5472.CAN-05-0259

Offord, 2020, Cancer researchers use evolution to target drug resistance, The Scientist

Ogura, 2013, Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer, J. Gastroenterol., 48, 640, 10.1007/s00535-012-0664-2

Oser, 2015, Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, Lancet Oncol., 16, e165, 10.1016/S1470-2045(14)71180-5

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med., 2, e73, 10.1371/journal.pmed.0020073

Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med., 2, e17, 10.1371/journal.pmed.0020017

Papa, 2019, The PTEN(-)PI3K axis in cancer, Biomolecules, 9, 10.3390/biom9040153

Pecoraro, 2021, GSK3beta as a novel promising target to overcome chemoresistance in pancreatic cancer, Drug Resist. Updat., 58, 10.1016/j.drup.2021.100779

Pellicer, 2011

Pon, 2015, Driver and passenger mutations in cancer, Annu. Rev. Pathol., 10, 25, 10.1146/annurev-pathol-012414-040312

Pontiggia, 2012, The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin, Breast Cancer Res. Treat., 133, 459, 10.1007/s10549-011-1766-x

Poulin, 2019, Tissue-specific oncogenic activity of KRAS(A146T), Cancer Discov., 9, 738, 10.1158/2159-8290.CD-18-1220

Prieto-Vila, 2019, Single-cell analysis reveals a preexisting drug-resistant subpopulation in the luminal breast cancer subtype, Cancer Res., 79, 4412, 10.1158/0008-5472.CAN-19-0122

Prior, 2012, A comprehensive survey of Ras mutations in cancer, Cancer Res., 72, 2457, 10.1158/0008-5472.CAN-11-2612

Prior, 2020, The frequency of ras mutations in cancer, Cancer Res., 80, 2969, 10.1158/0008-5472.CAN-19-3682

Pylayeva-Gupta, 2011, RAS oncogenes: weaving a tumorigenic web, Nat. Rev. Cancer, 11, 761, 10.1038/nrc3106

Rajasekharan, 2013, Ras and Ras mutations in cancer, Cent. Eur. J. Biol., 8, 609

Raso, 2020, Splice variants of RAS-translational significance, Cancer Metastasis Rev., 39, 1039, 10.1007/s10555-020-09920-8

Reiter, 2019, An analysis of genetic heterogeneity in untreated cancers, Nat. Rev. Cancer, 19, 639, 10.1038/s41568-019-0185-x

Rezaei Adariani, 2021, A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners, J. Biol. Chem., 296, 100626, 10.1016/j.jbc.2021.100626

Robey, 2018, Revisiting the role of ABC transporters in multidrug-resistant cancer, Nat. Rev. Cancer, 18, 452, 10.1038/s41568-018-0005-8

Rolfo, 2014, Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer, Curr. Pharm. Biotechnol., 15, 475, 10.2174/1389201015666140519123219

Ruan, 2020, A review of research progress in multidrug-resistance mechanisms in gastric cancer, Onco. Ther., 13, 1797, 10.2147/OTT.S239336

Rubio-Perez, 2015, In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities, Cancer Cell, 27, 382, 10.1016/j.ccell.2015.02.007

Russo, 2014, Mutational analysis and clinical correlation of metastatic colorectal cancer, Cancer, 120, 1482, 10.1002/cncr.28599

Sabnis, 2019, Principles of resistance to targeted Cancer therapy: lessons from basic and translational cancer biology, Trends Mol. Med., 25, 185, 10.1016/j.molmed.2018.12.009

Saito, 2020, Landscape and function of multiple mutations within individual oncogenes, Nature, 582, 95, 10.1038/s41586-020-2175-2

Saleem, 2019, The TICking clock of EGFR therapy resistance in glioblastoma: target Independence or target compensation, Drug Resist. Updat., 43, 29, 10.1016/j.drup.2019.04.002

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N. Engl. J. Med., 355, 2542, 10.1056/NEJMoa061884

Sarmento-Ribeiro, 2019, The emergence of drug resistance to targeted cancer therapies: clinical evidence, Drug Resist. Updat., 47, 10.1016/j.drup.2019.100646

Schmitt, 2018, Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-Positive leukemias, Clin. Cancer Res., 24, 5321, 10.1158/1078-0432.CCR-18-0167

Schoepfer, 2018, Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1, J. Med. Chem., 61, 8120, 10.1021/acs.jmedchem.8b01040

Sciarrillo, 2020, The role of alternative splicing in cancer: from oncogenesis to drug resistance, Drug Resist. Updat., 53, 100728, 10.1016/j.drup.2020.100728

Serebriiskii, 2019, Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients, Nat. Commun., 10, 3722, 10.1038/s41467-019-11530-0

Sergina, 2007, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3, Nature, 445, 437, 10.1038/nature05474

Seton-Rogers, 2020, KRAS-G12C in the crosshairs, Nat. Rev. Cancer, 20, 3, 10.1038/s41568-019-0228-3

Shahar, 2020, Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance, Drug Resist. Updat., 52, 100712, 10.1016/j.drup.2020.100712

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N. Engl. J. Med., 353, 123, 10.1056/NEJMoa050753

Simanshu, 2017, RAS proteins and their regulators in human disease, Cell, 170, 17, 10.1016/j.cell.2017.06.009

Smith, 2013, NMR-based functional profiling of RASopathies and oncogenic RAS mutations, Proc Natl Acad Sci U S A, 110, 4574, 10.1073/pnas.1218173110

Stark, 2012, Two novel germline KRAS mutations: expanding the molecular and clinical phenotype, Clin. Genet., 81, 590, 10.1111/j.1399-0004.2011.01754.x

Stephens, 2017, Tumor RAS gene expression levels are influenced by the mutational status of RAS genes and both upstream and downstream RAS pathway genes, Cancer Inform., 16, 10.1177/1176935117711944

Stommel, 2007, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies, Science, 318, 287, 10.1126/science.1142946

Su, 2021, Novel nanomedicines to overcome cancer multidrug resistance, Drug Resist. Updat., 58, 100777, 10.1016/j.drup.2021.100777

Sun, 2019, Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis, Cancer Med., 8, 3059, 10.1002/cam4.2190

Suva, 2013, Epigenetic reprogramming in cancer, Science, 339, 1567, 10.1126/science.1230184

Tamai, 2018, T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system, Sci. Rep., 8, 9966, 10.1038/s41598-018-27767-6

Tamborini, 2004, A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient, Gastroenterology, 127, 294, 10.1053/j.gastro.2004.02.021

Taniguchi, 2019, AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells, Nat. Commun., 10, 259, 10.1038/s41467-018-08074-0

Tate, 2019, COSMIC: the catalogue of somatic mutations in cancer, Nucleic Acids Res., 47, D941, 10.1093/nar/gky1015

Taylor, 2015, Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach, Drug Resist. Updat., 23, 69, 10.1016/j.drup.2015.08.004

Tomasetti, 2015, Only three driver gene mutations are required for the development of lung and colorectal cancers, Proc Natl Acad Sci U S A, 112, 118, 10.1073/pnas.1421839112

Tsai, 2015, K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif, Proc Natl Acad Sci U S A, 112, 779, 10.1073/pnas.1412811112

van der Wekken, 2016, Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature, Crit. Rev. Oncol. Hematol., 100, 107, 10.1016/j.critrevonc.2016.01.024

van Gastel, 2020, Induction of a timed metabolic collapse to overcome cancer chemoresistance, Cell Metab., 32, e396

Vasan, 2019, A view on drug resistance in cancer, Nature, 575, 299, 10.1038/s41586-019-1730-1

Vasan, 2019, Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kalpha inhibitors, Science, 366, 714, 10.1126/science.aaw9032

Volm, 2015, Prediction of cancer drug resistance and implications for personalized medicine, Front. Oncol., 5, 282, 10.3389/fonc.2015.00282

Wang, 2019, Drug resistance and combating drug resistance in cancer, Cancer Drug Resist., 2, 141

Wang, 2021, Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance, Drug Resist. Updat., 54, 100743, 10.1016/j.drup.2021.100743

Wijdeven, 2016, Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics, Drug Resist. Updat., 28, 65, 10.1016/j.drup.2016.07.001

Wilson, 2012, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, 487, 505, 10.1038/nature11249

Witkiewicz, 2015, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nat. Commun., 6, 6744, 10.1038/ncomms7744

Wojtkowiak, 2011, Drug resistance and cellular adaptation to tumor acidic pH microenvironment, Mol. Pharm., 8, 2032, 10.1021/mp200292c

Wylie, 2017, The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature, 543, 733, 10.1038/nature21702

Xu, 2013, Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation, Cancer Discov., 3, 993, 10.1158/2159-8290.CD-13-0096

Yan, 2020, Emerging roles of F-box proteins in cancer drug resistance, Drug Resist. Updat., 49, 100673, 10.1016/j.drup.2019.100673

Yang, 2018, Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients, BMC Bioinformatics, 19, 40, 10.1186/s12859-018-2011-y

You, 2012, Cancer genetics and epigenetics: two sides of the same coin?, Cancer Cell, 22, 9, 10.1016/j.ccr.2012.06.008

Zaal, 2018, The influence of metabolism on drug response in cancer, Front. Oncol., 8, 500, 10.3389/fonc.2018.00500

Zhang, 2010, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors, Nature, 463, 501, 10.1038/nature08675

Zhang, 2020, PI3K inhibitors: review and new strategies, Chem. Sci., 11, 5855, 10.1039/D0SC01676D

Zhang, 2021, PI3K driver mutations: a biophysical membrane-centric perspective, Cancer Res., 81, 237, 10.1158/0008-5472.CAN-20-0911

Zhitomirsky, 2015, Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance, Oncotarget, 6, 1143, 10.18632/oncotarget.2732

Zhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updat., 24, 23, 10.1016/j.drup.2015.11.004

Zhong, 2020, Wnt signaling and drug resistance in cancer, Mol. Pharmacol., 97, 72, 10.1124/mol.119.117978

Zhu, 2019, AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications, Mol. Cancer, 18, 153, 10.1186/s12943-019-1090-3

Zsakai, 2019, Targeted drug combination therapy design based on driver genes, Oncotarget, 10, 5255, 10.18632/oncotarget.26985